Association between BMI and Efficacy of SGLT2 Inhibitors in Patients with Heart Failure or at Risk of Heart Failure: A Meta-Analysis Based on Randomized Controlled Trials

Abstract

<b><i>Introduction:</i></b> This meta-analysis aimed to investigate the effect of SGLT2 inhibitors on the prognosis of patients with heart failure (HF) or at risk of HF across different body mass index (BMI). <b><i>Methods:</i></b> We searched PubMed, Embase, Web of Science, and Cochrane Library for all randomized controlled trials comparing SGLT2 inhibitors with placebo in patients with HF or at risk of HF and extracted relevant data up to April 2023 for meta-analysis. <b><i>Results:</i></b> A total of 29,500 patients were enrolled in the selected five studies. The results showed that patients treated with SGLT2 inhibitors had lower HF hospitalization (HHF) or cardiovascular (CV) mortality compared to those taking placebo (hazard ratio [HR] = 0.73, <i>p</i> &lt; 0.001). Patients taking SGLT2 inhibitors also had a lower all-cause mortality rate than those taking placebo (HR = 0.85, <i>p</i> = 0.017). In BMI subgroup analysis, the HHF rate in the experimental group was lower than that in the control group at BMI ≤24.9 kg/m², 25.0–29.9 kg/m², and ≥30.0 kg/m². There was no significant difference in CV mortality between the two groups at BMI ≤24.9 kg/m² (HR = 0.91, <i>p</i> = 0.331) and 25.0–29.9 kg/m² (HR = 0.92, <i>p</i> = 0.307). However, when the BMI was ≥30.0 kg/m², CV mortality with SGLT2 inhibitors was lower than in the control group (HR = 0.79, <i>p</i> = 0.002). When patients had a BMI ≤24.9 kg/m² (HR = 0.85, <i>p</i> = 0.033) and 25.0–29.9 kg/m² (HR = 0.83, <i>p</i> = 0.046), the all-cause mortality was lower in the experimental group than in the control group. However, there was no significant difference between the 2 groups in patients with a BMI ≥30.0 kg/m² (HR = 0.87, <i>p</i> = 0.094). <b><i>Conclusion:</i></b> SGLT2 inhibitors improve the prognosis in patients with HF or at risk of HF. This effect is affected by BMI.